Weekly Life Science News Round Up: 23rd – 27th May
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 23rd-27th May.
The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer medicines in low- and lower middle-income countries (LLMICs).
ICON plc has been recognised with a number of prestigious business and industry awards in April 2022, including Company of the Year at the 2021 Business & Finance Irish Business Awards and Pharma Contract Services Company of the Year at the Pharma Industry Awards 2021.
Pfizer today launched ‘An Accord for a Healthier World.’ This groundbreaking initiative aims to provide all of Pfizer’s patented, high-quality medicines and vaccines available in the U.S. or the European Union on a not-for-profit basis to 1.2 billion people in 45 lower-income countries.
Novartis UK has today announced the launch of a new heart failure Health Inequalities Insights Tool (HIIT) that draws on a range of health datasets to build a greater understanding of the relationship between heart failure and socioeconomic deprivation in England.
Sosei Group Corporation today announces it has expanded its UK R&D operations into a second site within Granta Park, Cambridge, to The Cori Building, previously occupied by Cancer Research UK.
The PPD clinical research business of Thermo Fisher Scientific has been recognized as one of the best in the world for its successful enterprise learning and development programs by the Association for Talent Development (ATD).
PrecisionLife Limited, an Oxford-based global techbio company generating deep insights into disease biology, is delighted to announce that it has been named a winner at the British Data Awards 2022.
Upperton Pharma Solutions (Upperton), a UK-based specialist contract development and manufacturing organisation (CDMO), has announced a circa. £15m investment into the design and build of a 50,000 sq ft facility in Nottingham.
Thermo Fisher Scientific and Qatar Genome Program (QGP) have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally.
Futura Medical plc today announces it has entered into an exclusive licensing agreement with Cooper Consumer Health (“Cooper”) for the rights to commercialise the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment MED3000, throughout the European Economic Area, United Kingdom and Switzerland.
Calibre Scientific is pleased to announce the acquisition of Serviquimia, a high-quality distributor of consumables, chemicals, lab equipment, and lab furniture, headquartered in Tarragona, Spain.
Qlucore is delighted to announce a new collaboration in the field of precision diagnostics to develop solutions for improved clinical diagnostics of bladder cancer. Bladder cancer is the third classifier model co-operation launched by Qlucore in the area of solid tumours.
Oxford BioTherapeutics (OBT) today announced that it has entered into a collaboration and supply agreement with Agenus Inc. to support a clinical trial evaluating the combination of OBT076 with the anti-PD1 checkpoint inhibitor (CPI) balstilimab.
Abbott (NYSE: ABT) today announced that the U.S. District Court for the Western District of Michigan has amended the recent consent decree allowing Abbott to release limited quantities of its EleCare® specialty amino acid-based formulas.
Bavarian Nordic A/S (OMX: BAVA) announced today the signing of a supply contract with an undisclosed country for the Company’s smallpox vaccine with the aim to ensure sufficient supply to meet the country’s requirements for vaccinating individuals at risk for monkeypox in the short to medium term.
See more of the latest Life Science news on PharmiWeb.com.